10 results
8-K
EX-1.1
NBRVF
Nabriva Therapeutics plc
25 Jun 19
Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin
5:03pm
8-K
EX-1.1
NBRVF
Nabriva Therapeutics plc
1 Aug 18
Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $50 Million
5:16pm
8-K
EX-1.1
NBRVF
Nabriva Therapeutics plc
16 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
NBRVF
Nabriva Therapeutics plc
20 Sep 17
Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares
12:00am
6-K
EX-1.1
NBRVF
Nabriva Therapeutics plc
15 Dec 16
The Bank of New York Mellon
12:00am
20-F
EX-1.2
gx8kmkv0
28 Apr 16
Annual report (foreign)
12:00am
20-F
EX-1.3
a3vgyfz
28 Apr 16
Annual report (foreign)
12:00am
F-6 POS
EX-1
n3pnv3 n5uhz
21 Sep 15
Automatic registration for ADRs (post-effective amendment, foreign)
12:00am
F-6
EX-1
509note
4 Sep 15
Registration for ADRs (foreign)
12:00am
F-1/A
EX-1.1
emzxnf2pgcdcpyi
24 Aug 15
Registration statement (foreign) (amended)
12:00am
- Prev
- 1
- Next